HUP0000843A3 - New formulation for inhalation having a poured bulnew formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising fok density of from 0,28 to 0,38 g/ml, comprising formoterol rmoterol - Google Patents

New formulation for inhalation having a poured bulnew formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising fok density of from 0,28 to 0,38 g/ml, comprising formoterol rmoterol

Info

Publication number
HUP0000843A3
HUP0000843A3 HU00008430000843A HUP0000843A HUP0000843A3 HU P0000843 A3 HUP0000843 A3 HU P0000843A3 HU 00008430000843 A HU00008430000843 A HU 00008430000843A HU P0000843 A HUP0000843 A HU P0000843A HU P0000843 A3 HUP0000843 A3 HU P0000843A3
Authority
HU
Hungary
Prior art keywords
inhalation
poured
formulation
density
rmoterol
Prior art date
Application number
HU00008430000843A
Other languages
English (en)
Original Assignee
Astra Aktiebolag Soedertalje A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0000843(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag Soedertalje A filed Critical Astra Aktiebolag Soedertalje A
Publication of HUP0000843A2 publication Critical patent/HUP0000843A2/hu
Publication of HUP0000843A3 publication Critical patent/HUP0000843A3/hu
Publication of HU228682B1 publication Critical patent/HU228682B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0000843A 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising formoterol, its preparation and its use HU228682B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700134A SE9700134D0 (sv) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000039 WO1998031351A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol

Publications (3)

Publication Number Publication Date
HUP0000843A2 HUP0000843A2 (hu) 2000-09-28
HUP0000843A3 true HUP0000843A3 (en) 2000-10-30
HU228682B1 HU228682B1 (en) 2013-05-28

Family

ID=20405453

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000843A HU228682B1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising formoterol, its preparation and its use

Country Status (32)

Country Link
EP (1) EP1009394B1 (hu)
JP (2) JP4512203B2 (hu)
KR (1) KR100528417B1 (hu)
CN (1) CN1213741C (hu)
AT (1) ATE257699T1 (hu)
AU (1) AU728835B2 (hu)
BE (1) BE1011401A3 (hu)
BR (1) BR9806895A (hu)
CA (1) CA2277890C (hu)
CZ (1) CZ295682B6 (hu)
DE (1) DE69821119T2 (hu)
DK (1) DK1009394T3 (hu)
EE (1) EE04038B1 (hu)
ES (2) ES2212262T3 (hu)
FR (1) FR2759907B1 (hu)
GR (1) GR980100022A (hu)
HU (1) HU228682B1 (hu)
ID (1) ID21917A (hu)
IE (1) IE980025A1 (hu)
IL (1) IL130837A0 (hu)
IS (1) IS2243B (hu)
NL (1) NL1008021C2 (hu)
NO (1) NO327457B1 (hu)
NZ (1) NZ336593A (hu)
PL (1) PL189552B1 (hu)
PT (1) PT1009394E (hu)
RU (1) RU2180220C2 (hu)
SE (1) SE9700134D0 (hu)
SK (1) SK283949B6 (hu)
TR (1) TR199901692T2 (hu)
UA (1) UA57763C2 (hu)
WO (1) WO1998031351A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
EP2821061B1 (en) 2013-07-01 2017-12-20 Arven Ilac Sanayi Ve Ticaret A.S. Novel inhalation formulations
WO2015060743A1 (ru) * 2013-10-21 2015-04-30 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения
AU2020356243A1 (en) 2019-09-24 2022-03-24 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
ATE17441T1 (de) * 1981-07-24 1986-02-15 Fisons Plc Inhalierbare arzneimittel, verfahren zu deren herstellung und pharmazeutische formulierungen diese enthaltend.
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
CN1110300C (zh) * 1993-10-01 2003-06-04 阿斯特拉公司 工艺技术ⅰ
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination

Also Published As

Publication number Publication date
FR2759907B1 (fr) 2001-03-09
ES2149082A1 (es) 2000-10-16
CN1243435A (zh) 2000-02-02
UA57763C2 (uk) 2003-07-15
PL334528A1 (en) 2000-02-28
CZ295682B6 (cs) 2005-09-14
CA2277890C (en) 2006-08-29
ATE257699T1 (de) 2004-01-15
AU5785898A (en) 1998-08-07
PT1009394E (pt) 2004-05-31
SE9700134D0 (sv) 1997-01-20
DE69821119D1 (de) 2004-02-19
ES2149082B1 (es) 2001-05-16
DE69821119T2 (de) 2004-08-19
SK95899A3 (en) 2000-01-18
CN1213741C (zh) 2005-08-10
IE980025A1 (en) 1998-10-07
EP1009394A1 (en) 2000-06-21
FR2759907A1 (fr) 1998-08-28
BE1011401A3 (fr) 1999-08-03
NO993538L (no) 1999-09-17
NO327457B1 (no) 2009-07-06
NL1008021A1 (nl) 1998-07-22
NO993538D0 (no) 1999-07-19
SK283949B6 (sk) 2004-05-04
CA2277890A1 (en) 1998-07-23
IL130837A0 (en) 2001-01-28
GR980100022A (el) 1998-09-30
JP2001508792A (ja) 2001-07-03
KR100528417B1 (ko) 2005-11-16
NL1008021C2 (nl) 1998-10-07
ES2212262T3 (es) 2004-07-16
KR20000070187A (ko) 2000-11-25
HUP0000843A2 (hu) 2000-09-28
CZ255699A3 (cs) 1999-10-13
HU228682B1 (en) 2013-05-28
RU2180220C2 (ru) 2002-03-10
WO1998031351A1 (en) 1998-07-23
IS2243B (is) 2007-05-15
JP2010059180A (ja) 2010-03-18
EP1009394B1 (en) 2004-01-14
NZ336593A (en) 2001-01-26
DK1009394T3 (da) 2004-04-05
JP4512203B2 (ja) 2010-07-28
IS5109A (is) 1999-07-06
PL189552B1 (pl) 2005-08-31
TR199901692T2 (xx) 1999-09-21
AU728835B2 (en) 2001-01-18
BR9806895A (pt) 2000-05-16
ID21917A (id) 1999-08-12
EE9900294A (et) 2000-02-15
EE04038B1 (et) 2003-06-16

Similar Documents

Publication Publication Date Title
IL130838A0 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml a process for preparing the formulation and the use thereof
HUP0000843A3 (en) New formulation for inhalation having a poured bulnew formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising fok density of from 0,28 to 0,38 g/ml, comprising formoterol rmoterol
HUP0000841A3 (en) New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising budesonide and process for its preparation
HUP0000755A3 (en) New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
SI1009394T1 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
IL162864A (en) Formulation for inhalation having a poured bulk density of from 0.28 to 0.38g/ml, comprising formoterol

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ASTRAZENECA AB, SOEDERTAELJE, SE

Free format text: FORMER OWNER(S): ASTRA AKTIEBOLAG, SE

TH4A Erratum